Skip to main content

Health Care

Jump To:

Recent Reports

View More Reports

Open Recommendations

VA Health Care: Efforts to Assess Mental Health Support for Veteran Caregiver Program Need Strengthening
GAO-26-108070
Apr 16, 2026
Show
2 Open Recommendations
Agency Affected Recommendation Status
Department of Veterans Affairs The Secretary of the Department of Veterans Affairs should ensure the Under Secretary for Health implements key performance management practices to increase the awareness of the Caregiver Support Program by (1) establishing quantitative targets and time frames for all of its program goals, such as increasing the number of program inquiries, and (2) using these data to assess program performance and make adjustments as appropriate. (Recommendation 1)
Open
When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information.
Department of Veterans Affairs The Secretary of the Department of Veterans Affairs should ensure the Under Secretary for Health implements key performance management practices to assess the mental health support offered by the Caregiver Support Program by (1) establishing goals with quantitative targets and time frames for all of the mental health support offered through the program, including referrals for mental health care provided at VA medical facilities; (2) collecting performance information to measure progress towards meeting these goals, and (3) using these data to assess program performance and make adjustments as appropriate. (Recommendation 2)
Open
When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information.

FDA Advisory Committees: More Transparency Needed on Policies for Making Conflict of Interest Determinations
GAO-26-107877
Mar 24, 2026
Show
3 Open Recommendations
Agency Affected Recommendation Status
Food and Drug Administration The Commissioner of FDA should establish a time frame for issuing and publicly sharing required guidance on how the agency determines financial conflicts of interest for advisory committee members. (Recommendation 1)
Open
When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information.
Food and Drug Administration The Commissioner of FDA should post to the agency's advisory committee program website information on how FDA determines whether advisory committee members have financial conflicts of interest and how FDA determines whether they should participate in committee meetings. For example, FDA could post the information it is using to make these determinations while the required guidance is being updated. (Recommendation 2)
Open
When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information.
Food and Drug Administration The Commissioner of FDA should post to the agency's advisory committee program website information, such as a guidance document, on how FDA determines whether advisory committee guest speakers have financial conflicts of interest and appearance issues, and how FDA determines whether they should participate in committee meetings. (Recommendation 3)
Open
When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information.

Animal Drugs: Strengthening Federal Incentives Could Help Address Unmet Animal Health Needs
GAO-26-107896
Mar 03, 2026
Show
3 Open Recommendations
Agency Affected Recommendation Status
Congress Congress should consider whether the statutory 5-year limit on conditional approval for animal drugs should be expanded to appropriately balance the goals of increasing drug availability to address unmet animal health needs, protecting animal and human health, and maintaining incentives for sponsors to develop drugs for markets with limited profitability, and should amend the statute as appropriate.
Open
When we confirm what actions Congress has taken in response to this recommendation, we will provide updated information.
Food and Drug Administration The Commissioner of FDA should incorporate a benefit-risk assessment into its process for evaluating whether animal drugs that use alternative study designs have demonstrated substantial evidence of effectiveness. (Recommendation 1)
Open
When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information.
Food and Drug Administration The Commissioner of FDA should develop guidance for industry on its use of benefit-risk assessments in its regulatory decisions for animal drugs that demonstrate substantial evidence of effectiveness using alternative study designs. (Recommendation 2)
Open
When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information.

Sexual Health Education: HHS Could Improve Efforts to Assess Grantee Performance
GAO-26-107617
Mar 02, 2026
Show
1 Open Recommendations
Agency Affected Recommendation Status
Administration for Children and Families The Administrator of ACF should identify and implement appropriate near-term goals with specific targets and time frames for the performance measures related to youth outcomes and program experiences for the SRAE programs. (Recommendation 1)
Open
When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information.
View More Recommendations

Related Pages

GAO Contacts

Multimedia

Podcasts

Preventing Fraud in Medicare
Transcript
FDA's Efforts to Recall Faulty Medical Devices Limited by Insufficient Staffing
Transcript
Mental Health Screenings for Military Service Members Transitioning to Civilian Life
Transcript